Tuoxin Pharmaceutical Group Co.,Ltd. (SHE:301089)
China · Delayed Price · Currency is CNY 34.72
+0.23 (0.67%)
Last updated: Jul 17, 2025
SHE:301089 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | -25.52 | -19.88 | 243.07 | 286.54 | 65.71 | 112.8 | Upgrade |
Depreciation & Amortization | 47.66 | 47.66 | 46.59 | 40.52 | 30.92 | 17.39 | Upgrade |
Other Amortization | 0.88 | 0.88 | 0.52 | 0.47 | 0.57 | 0.6 | Upgrade |
Loss (Gain) From Sale of Assets | 0.01 | 0.01 | - | -0.03 | - | 0.23 | Upgrade |
Asset Writedown & Restructuring Costs | 1.42 | 1.42 | 4.22 | 1.03 | 1.34 | 0.98 | Upgrade |
Loss (Gain) From Sale of Investments | -1.55 | -1.55 | -7.12 | -5.77 | -0.63 | -0.66 | Upgrade |
Provision & Write-off of Bad Debts | 4.08 | 4.08 | 4.48 | -5.11 | 2.28 | 0.13 | Upgrade |
Other Operating Activities | -64.61 | 9.92 | 11.11 | 12.48 | 9.5 | 13.92 | Upgrade |
Change in Accounts Receivable | 72.83 | 72.83 | -57.67 | -100.76 | -27.49 | -22.27 | Upgrade |
Change in Inventory | 14.55 | 14.55 | 37.75 | -72.92 | -21.38 | -47.43 | Upgrade |
Change in Accounts Payable | -19.28 | -19.28 | -264.08 | 172.6 | -61.71 | -10.29 | Upgrade |
Change in Unearned Revenue | - | - | - | - | 16.83 | 15.82 | Upgrade |
Change in Other Net Operating Assets | - | - | - | - | 40.99 | 38.49 | Upgrade |
Operating Cash Flow | 22.51 | 102.67 | 26.95 | 268.85 | 58.19 | 120 | Upgrade |
Operating Cash Flow Growth | - | 280.91% | -89.98% | 361.99% | -51.51% | 38.93% | Upgrade |
Capital Expenditures | -79.13 | -83.91 | -185.22 | -148.33 | -112.73 | -74.12 | Upgrade |
Sale of Property, Plant & Equipment | 0.59 | 0.6 | 0.04 | 0.08 | 10 | 0.08 | Upgrade |
Investment in Securities | -60 | -60 | 56.57 | -20.4 | -220 | - | Upgrade |
Other Investing Activities | 3.87 | 3.43 | - | 6.24 | - | 0.65 | Upgrade |
Investing Cash Flow | -134.67 | -139.88 | -128.61 | -162.41 | -322.73 | -73.39 | Upgrade |
Short-Term Debt Issued | - | - | - | 90 | 131.4 | - | Upgrade |
Long-Term Debt Issued | - | - | - | - | - | 244.76 | Upgrade |
Total Debt Issued | - | - | - | 90 | 131.4 | 244.76 | Upgrade |
Short-Term Debt Repaid | - | - | - | - | -193.82 | - | Upgrade |
Long-Term Debt Repaid | - | -0.94 | -40 | -115.42 | -44.93 | -228.31 | Upgrade |
Total Debt Repaid | -0.94 | -0.94 | -40 | -115.42 | -238.75 | -228.31 | Upgrade |
Net Debt Issued (Repaid) | -0.94 | -0.94 | -40 | -25.42 | -107.35 | 16.45 | Upgrade |
Issuance of Common Stock | - | - | 21.6 | - | 558.81 | - | Upgrade |
Common Dividends Paid | -31.64 | -31.64 | -50.67 | -14.98 | -7.92 | -9.6 | Upgrade |
Dividends Paid | -31.64 | -31.64 | -50.67 | -14.98 | -7.92 | -9.6 | Upgrade |
Other Financing Activities | - | - | - | - | -11.3 | -0.59 | Upgrade |
Financing Cash Flow | -32.57 | -32.57 | -69.07 | -40.4 | 432.23 | 6.26 | Upgrade |
Foreign Exchange Rate Adjustments | 0.76 | 0.83 | 0.11 | 0.97 | -0.73 | -0.42 | Upgrade |
Net Cash Flow | -143.97 | -68.95 | -170.62 | 67.01 | 166.97 | 52.45 | Upgrade |
Free Cash Flow | -56.62 | 18.76 | -158.27 | 120.52 | -54.53 | 45.88 | Upgrade |
Free Cash Flow Growth | - | - | - | - | - | 350.96% | Upgrade |
Free Cash Flow Margin | -13.80% | 4.45% | -18.94% | 15.36% | -10.85% | 8.69% | Upgrade |
Free Cash Flow Per Share | -0.44 | 0.15 | -1.26 | 0.95 | -0.55 | 0.48 | Upgrade |
Cash Income Tax Paid | 0.54 | -7.98 | 237 | 56.09 | 20.74 | 29.6 | Upgrade |
Levered Free Cash Flow | -37.11 | 34.73 | -156.56 | 106.83 | -139.19 | 58.7 | Upgrade |
Unlevered Free Cash Flow | -37.05 | 34.76 | -156.35 | 108.94 | -133.48 | 67.37 | Upgrade |
Change in Net Working Capital | -23.16 | -95.85 | 205.57 | -23.91 | 104.69 | -35.4 | Upgrade |
Updated Oct 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.